We demonstrate MTHFD2 inhibitors being well tolerated and more efficient than standard of care in AML in-vivo models, and provide evidence of strong synergy with ATR inhibitors and dUTPase inhibitors that may improve current anticancer treatments. Here, ATR is linked to acute myeloid leukemia.